阿托伐他汀与瑞舒伐他汀治疗CSAS合并心力衰竭的效果及对睡眠质量影响

The Effect of Atorvastatin and Rosuvastatin in the Treatment of CSAs with Heart Failure and its Effect on Sleep Quality

目的:探讨阿托伐他汀与瑞舒伐他汀治疗CSAS合并心力衰竭的效果及对睡眠质量的影响。方法:选取2018年6月至2019年6月曲阜市人民医院收治的CSAS合并心力衰竭患者110例作为研究对象,随机分为A组和B组,每组55例。A组采用阿托伐他汀治疗,B组采用瑞舒伐他汀治疗。比较2组治疗效果。结果:2组患者治疗前相关指标比较,差异无统计学意义(P> 0. 05)。治疗后,2组患者的血脂水平和ET-1、Scr、hs-CRP、NT-pro BNP等指标均有明显改善(P <0. 05);且B组TG水平及TC水平明显低于A组,A组AHI以及觉醒次数明显低于B组,2组比较差异均有统计学意义(P <0. 05)。结论:给予CSAS合并心力衰竭患者实施阿托伐他汀与瑞舒伐他汀治疗效果好,而且前者在降低AHI以及觉醒次数上效果更好,后者在降低患者TG以及TC水平上效果更好。

Objective:To explore the effect of atorvastatin and rosuvastatin on the treatment of CASS with heart failure and sleep quality.Methods:A total of 110 patients with CSAS and heart failure who were treated in Qufu people′s Hospital from June 2018 to June 2019 were randomly divided into two groups of 55 patients each.treatment.Results:There was no statistically significant difference between the two groups before treatment.After treatment,the TG and TC levels in group B were significantly lower than those in group A,and the AHI and the number of awakenings in group A were significantly lower than those in group B(P<0.05),which was statistically significant.Conclusion:Atorvastatin and rosuvastatin are effective in patients with heart failure who are given CASS and statin,and the former is better at reducing AHI and the number of awakenings,and the latter is better at reducing TG and TC levels in patients.